Securities Purchase Agreement



 Exhibit 10.127 
 CORTEX PHARMACEUTICALS, INC. 
 SECURITIES PURCHASE AGREEMENT

 This Securities Purchase Agreement (the “Agreement”) is entered into as of October 20, 2011 (the
“Effective Date”), between Cortex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Samyang Value Partners Co., Ltd., a South Korean corporation (the “Purchaser”). 

R E C I T A L S: 
 Purchaser desires to purchase, and the Company desires to sell and issue to Purchaser, shares of common stock and related warrants to purchase common stock of the Company, with a par value of US$0.001 per
share, in accordance with the terms and conditions of the Agreement. 
 A G R E E M E N T: 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the parties agree as follows: 

1. Definitions. Capitalized terms used in the Agreement and not otherwise defined herein shall have the meanings set forth on
Annex A hereto. 
 2. Sale and Issuance of the Shares and Warrants. 

(a) Subject to the satisfaction of the terms and conditions of the Closing set forth herein and in reliance upon the respective
representations and warranties of the parties set forth herein or in any document delivered pursuant hereto, the Company agrees to issue and sell to Purchaser upon the Closing such number of shares of its Common Stock equal to the Purchase Price
divided by the Weighted Average Closing Price of the Common Stock for the five (5) Trading Day period immediately prior to the Effective Date. The parties hereby agree that the number of shares shall equal 6,765,466 and the deemed purchase
price per share shall be approximately $0.0739. 
 (b) Concurrently with the issuance of the Shares in subparagraph
(a) above, upon the Closing the Purchaser shall be issued Warrants to purchase a number of shares of Common Stock equal to twenty-five percent (25%) of the total number of Shares. The initial exercise price of the Warrants shall be an
amount per share of Common Stock equal to one hundred forty percent (140%) of the price per Share calculated in subparagraph (a) above. The Warrants shall be in the form attached hereto as Exhibit A. The parties hereby agree that
the number of shares subject to the Warrant shall equal 1,691,367 and the deemed exercise price per share shall be $0.1035. 
 3. Delivery of the Shares and Warrants at the Closing. The closing of the purchase and sale of the Shares and the Warrants contemplated hereunder (the “Closing”) shall be held as
of the same date herewith or at such other time upon which the Company and the Purchaser shall mutually agree (the “Closing Date”); provided, however, that to the extent that the Company has not received the Purchase
Price on or prior to the seventh (7th) Business Day
following the Effective Date, unless the Company otherwise expressly agrees in writing, this Agreement shall automatically terminate without penalty to the Company. On the Closing Date, the Company shall have received from the Purchaser via wire
transfer an amount equal to the Purchase Price and the Company will issue and deliver to the Purchaser the Shares and the Warrants. 







 4. Purchaser’s Representations. The Purchaser hereby represents and warrants to
the Company as follows: 
 (a) The Purchaser is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by hereby and otherwise to carry out its obligations hereunder. 

(b) The execution and delivery of the Agreement and performance by the Purchaser of the transactions contemplated by the Agreement have
been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of the Purchaser. 
 (c) The Agreement has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the
Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be
limited by applicable law. 
 (d) The execution, delivery and performance by the Purchaser of the Agreement and the consummation
by it of the transactions contemplated thereby do not and will not (i) conflict with or violate any provision of the Purchaser’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or
(ii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Purchaser is subject (including federal and state securities
laws and regulations), or by which any property or asset of the Purchaser is bound or affected, except in the case subparagraph (ii) such as could not have or reasonably be expected to have a material adverse effect on the Purchaser.

 (e) The Purchaser is acquiring the Shares and the Warrants, as well as the shares of Common Stock underlying the Warrants, if
any (collectively referred to with the Shares and Warrants as the “Securities”), for the Purchaser’s own account and not as a nominee or agent for any other person, and not with the view to, or for sale in connection with, any
distribution thereof. 
 (f) The Purchaser is an “accredited investor,” as the Purchaser is a person or entity
described in one of the items in Annex B attached hereto. 
 (g) The Purchaser is not purchasing the Securities as a
result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or
general advertisement. 
 (h) The Purchaser understands that the Securities are being offered and sold to it in reliance upon
specific exemptions from the registration requirements of federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements,
acknowledgements and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities. 

(i) The offer and sale of the Securities has not been registered under the Securities Act, and that, accordingly, they will not be
transferable except as permitted under various exemptions set 

  
 2 








 
forth in the Securities Act, or upon satisfaction of the registration and prospectus delivery requirements of the Securities Act, and that there will be a legend printed upon the Securities so
indicating. 
 (j) The Securities may not be sold, transferred, assigned, pledged, hypothecated or otherwise disposed of unless
the Purchaser first provides to the Company an opinion of counsel to the effect that such sale, transfer, assignment, pledge, hypothecation or other disposition will be exempt from the registration and prospectus delivery requirements of the
Securities Act and the registration or qualification requirements of any applicable state securities’ law. 
 5.
Company’s Representations. The Company hereby represents and warrants to the Purchaser as follows: 
 (a) The
Company is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions
contemplated by hereby and otherwise to carry out its obligations hereunder. 
 (b) The execution and delivery of the Agreement
and performance by the Company of the transactions contemplated by the Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of the Company. 

(c) The Agreement has been duly executed by the Company, and when delivered by the Company in accordance with the terms hereof, will
constitute the valid and legally binding obligation of the Company, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar
as indemnification and contribution provisions may be limited by applicable law. 
 (d) The execution, delivery and performance
by the Company of the Agreement and the consummation by it of the transactions contemplated thereby do not and will not (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except in the case subparagraph (ii) such as could not have or reasonably be expected to have a material
adverse effect on the Company. 
 (e) The authorized and outstanding capital stock of the Company is set forth on Annex C
attached hereto. All issued and outstanding shares have been duly authorized and validly issued and are fully paid and nonassessable. Except as set forth on Annex C, there are no other outstanding rights, options, warrants, preemptive rights,
rights of first refusal, or similar rights for the purchase or acquisition from the Company of any securities of the Company nor are there any commitments to issue or execute any such rights, options, warrants, preemptive rights or rights of first
refusal. Except as otherwise provided in the Company’s certificate of incorporation, there are no outstanding rights or obligations of the Company to repurchase or redeem any of its securities. The respective rights, preferences, privileges,
and restrictions of the Company’s outstanding shares are as stated in the Company’s certificate of incorporation. All outstanding securities have been issued in compliance with all applicable securities laws. 

  
 3 








 (f) There is no action, suit, proceeding, or investigation (including without limitation any
suit, proceeding, or investigation involving the prior employment of any of the Company’s employees, their use in connection with the Company’s business of any information or techniques allegedly proprietary to any of their former
employers, or their obligations under any agreements with prior employers) against or adverse to the Company pending or, to the best of the Company’s knowledge, currently threatened before any court, administrative agency, or other governmental
body. The Company is not a party or subject to, and none of its assets is bound by, the provisions of any order, writ, injunction, judgment, or decree of any court or government agency or instrumentality. There is no action, suit, or proceeding by
the Company currently pending or that the Company intends to initiate. 
 (g) The Company has fully provided the Purchaser with
all the information that the Purchaser has requested for deciding whether to purchase the Shares and the Warrants. Neither this Agreement, nor any other agreements, statements or certificates made or delivered in connection herewith or therewith
contains any untrue statement of a material fact or, when taken together, omits to state a material fact necessary to make the statements herein or therein, in light of the circumstances under which they were made, not misleading. 

6. Conditions to Closing of the Purchaser. The Purchaser’s obligation to purchase the Shares and the Warrants at Closing in
accordance with the terms set forth herein is subject to the fulfillment on or prior to the Closing Date of each of the following conditions: 
 (a) Representations and Warranties Correct. The representations and warranties made by the Company in Section 5 hereof shall be true and correct when made and shall be true and correct on and
as of the Closing Date with the same force and effect as if they had been made on and as of said date. 
 (b) Covenants.
All covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to the Closing Date shall have been performed or complied with in all material respects. 

(c) No Material Adverse Change. There shall have been no material adverse change in the Company’s business or financial
condition. 
 7. Conditions to Closing of the Company. The Company’s obligation to issue and sell the Shares and the
Warrants at Closing in accordance with the terms set forth herein is subject to the fulfillment on or prior to the Closing Date of each of the following conditions: 
 (a) Representations and Warranties Correct. The representations and warranties made by the Purchaser in Section 4 hereof shall be true and correct when made and shall be true and correct on
and as of the Closing Date with the same force and effect as if they had been made on and as of said date. 
 (b)
Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by the Purchaser on or prior to the Closing Date shall have been performed or complied with in all material respects. 

8. Right of First Refusal. The Shares and the shares of Common Stock underlying the Warrants (the “Subject
Shares”) may be sold by the Purchaser only in compliance with the provisions of this Section 8, and subject in all cases to compliance with applicable securities laws. Prior to any intended sale of more than an aggregate of 500,000
Subject Shares in any two (2) Business Day period, the Purchaser shall first give written notice (the “Offer Notice”) to the Company specifying (i) its bona 

  
 4 








 
fide intention to sell or otherwise transfer such Subject Shares and (ii) the number of Subject Shares the Purchaser proposes to sell (the “Offered Shares”). Within two
(2) Business Days after receipt of the Offer Notice, the Company or its nominee(s) may elect to negotiate in good faith with the Purchaser to purchase all (not some) of such Offered Shares. In the event that the Company elects to purchase all
(not some) of such Offered Shares, the Purchaser and the Company shall negotiate in good faith to consummate a transaction for such Offered Shares within five (5) Business Days following the Company’s election. If the Company and the
Purchaser fail to agree upon a purchase price following good faith negotiation between the Company and the Purchaser, or otherwise any single share of the Offered Shares is not to be purchased by the Company, all the Offered Shares may be sold by
the Purchaser without any of the restrictions set forth in this Section 7. 
 9. “Market Stand-Off”
Agreement. The Purchaser agrees that, if requested by the Company or the managing underwriter of any proposed public offering of the Company’s securities, the Purchaser will not sell or otherwise transfer or dispose of any shares of Common
Stock held by the Purchaser without the prior written consent of the Company or such underwriter, as the case may be, during such period of time, not to exceed 180 days following the effective date of the registration statement filed by the Company
with respect to such offering, as the Company or the underwriter may specify. In order to enforce the foregoing covenant, the Company may impose stop transfer instructions with respect to any shares of Common Stock held by the Purchaser until the
end of such period. 
 10. Observer and Information Rights. If, and for such time as, the Purchaser owns not less than
fifteen percent (15%) of the then outstanding shares of Common Stock, (i) the Purchaser may, at its sole election, appoint a representative reasonably acceptable to the Company to attend all meetings of the Company’s Board of
Directors in a nonvoting observer capacity and, in this respect, the Company shall deliver to such representative of the Purchaser copies of all notices, minutes, consents, and other materials that it provides to its directors generally, and
(ii) the Purchaser shall be entitled to receive access to the Company’s quarterly financial statements and at least semi-annual updates on the status of the Company’s compound developments on or about the same time as provided to the
Company’s Board of Directors; provided, however, that in each case, such representative of the Purchaser (and the Purchaser) shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so
provided, and shall cause their respective agents and affiliates, as applicable, to do the same; and provided further, that the Company reserves the right to withhold any information from the representative and the Purchaser and, as
applicable, to exclude such representative of the Purchaser from any meeting or portion thereof, if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or
result in disclosure of trade secrets or a conflict of interest. In exercising its rights hereunder, the Purchaser expressly acknowledges and agrees that it shall not, and shall cause its agents, affiliates and representatives to not, utilize such
information provided hereunder other than for purposes consistent with the Company’s best interests and shall not acquire or dispose of any of the Company’s securities in violation of securities laws. 

11. Miscellaneous. 
 (a) Binding on Successors. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 

(b) Entire Agreement. This Agreement and the exhibits hereto, constitute the entire agreement between the parties with respect to
the subject matter hereof and supersedes all prior and contemporaneous agreements, whether written or oral, and shall not be modified except by a writing signed by the parties hereto. 

  
 5 








 (c) Governing Law. All questions concerning the construction, validity, enforcement
and interpretation of the Agreement shall be governed by and construed and enforced in accordance with the laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be
commenced exclusively in the courts sitting in Hong Kong. Each party hereby irrevocably submits to the exclusive jurisdiction of the courts sitting in Hong Kong for the adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect to the enforcement of the Agreement), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action or
proceeding to enforce any provisions of the Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding. 
 (d) Headings; References. All headings used
herein are used for convenience only and shall not be used to construe or interpret this Agreement. Except as otherwise indicated, all references herein to Sections refer to Sections hereof. 

(e) No Waiver. No waiver of any of the provisions contained in this Agreement shall be valid unless made in writing and executed
by the waiving party. It is expressly understood that in the event any party shall on any occasion fail to perform any term of this Agreement and the other parties shall not enforce that term, the failure to enforce on that occasion shall not
prevent enforcement of that or any other term hereof on any other occasion. 
 (f) Severability. If any section of this
Agreement is held invalid by any law, rule, order, regulation, or promulgation of any jurisdiction, such invalidity shall not affect the enforceability of any other sections not held to be invalid. 

(g) Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if properly addressed:
(i) if delivered personally, by commercial delivery service or by facsimile (with acknowledgment of a complete transmission prior to 5:30 p.m. Los Angeles time), on the day of delivery, (ii) if delivered by U.S. nationally recognized
overnight courier service, on the next Business Day after mailing, or (iii) upon actual receipt by the party to whom such notice is required by be given. 
 Notices shall be deemed to be deemed properly addressed to any party hereto if addressed to the following addresses (or at such other address for a party as shall be specified by like notice): 


  
 6 









	 	(i)	if to Purchaser, to: 

 Samyang Value Partners Co., Ltd. 
 Seoyeong Bldg. 12F 

158-12 Samsung Dong 
 Gangnam Gu 
 Seoul, Korea 

Attention: 
 Telephone: 
 Facsimile: 

Email: 
  

	 	(ii)	if to the Company: 

 Cortex Pharmaceuticals, Inc. 
 15231 Barranca Parkway 

Irvine, California 92618 
 Attention: Chief Executive Officer 
 Telephone:
(949) 727-3157 
 Facsimile: (949) 727-3657 

Email: mvarney@cortexpharm.com 
 with a copy to (which shall not constitute notice): 
 Stradling
Yocca Carlson & Rauth 
 660 Newport Center Drive, Suite 1600 

Newport Beach, CA 92660 
 Attention: Lawrence B. Cohn 
 Telephone: (949) 725-4000

 Facsimile: (949) 725-4100 

Email: lcohn@sycr.com 
 (h) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. 

(i) Counterparts. This Agreement and any amendment thereof may be executed in two or more counterparts, each of which shall be
deemed an original for all purposes. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 
 (j) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such
action may be taken or such right may be exercised on the next succeeding Business Day. 
 ********************* 

(Signature Page Follows) 

  
 7 








 The Company and the Purchaser have executed this Agreement as of the Effective Date.

  

			
	“Company”
	
	CORTEX PHARMACEUTICALS, INC.
		
	 By:
	 	  

		 	Mark A. Varney, Ph.D.
		 	President and Chief Executive Officer
	
	“Purchaser”
	
	SAMYANG VALUE PARTNERS CO., LTD.
		
	 By:
	 	  

		 	Soung Jin Kim
		 	President and Chief Executive Officer



  
 8 








 ANNEX A 

Definitions 
 “Agreement” shall mean this Securities Purchase Agreement. 

“Business Day” shall mean any day except any Saturday, any Sunday, any day which is a federal legal holiday in the
United States or any day on which banking institutions in the State of California are authorized or required by law or other governmental action to close. 
 “Closing” shall have the meaning set forth in Section 3 of the Agreement. 
 “Closing Date” shall have the meaning set forth in Section 3 of the Agreement. 
 “Common Stock” shall mean common stock of the Company, par value of US$0.001 per share. 
 “Company” shall mean Cortex Pharmaceuticals, Inc., a Delaware corporation. 
 “Effective Date” shall have the meaning set forth in the preambles to the Agreement. 
 “Offer Notice” shall have the meaning set forth in Section 8 of the Agreement. 
 “Offered Shares” shall have the meaning set forth in Section 8 of the Agreement. 
 “Purchase Price” shall mean US$500,000. 

“Purchaser” shall mean Samyang Value Partners Co., Ltd., a South Korean corporation. 

“Securities” shall have the meaning set forth in Section 4(e) of the Agreement. 

“Securities Act” shall mean the Securities Act of 1933, as amended. 

“Shares” shall mean the shares of Common Stock which are to be purchased pursuant to Section 2(a) of the Agreement.

 “Subject Shares” shall have the meaning set forth in Section 8 of the Agreement. 

“Trading Day” shall mean a day on which the principal Trading Market is open for trading. 

“Trading Market” shall mean a market or exchange on which the Common Stock is then listed or quoted for trading,
including, without limitation, the NYSE Amex Equities Market, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange, the OTC Bulletin Board or a Pink OTC Market (or any successors to any
of the foregoing). 
 “Warrants” shall mean the warrants to purchase shares of Common Stock which are to be
purchased pursuant to Section 2(b) of the Agreement. 
 “Weighted Average Closing Price” shall mean the
price determined by the first of the following clauses that applies: (A) if the Common Stock is then listed or quoted for trading on a Trading Market other than the OTC Bulletin Board or the Pink OTC Market, the volume-weighted average closing
prices of the Common Stock on the Trading Market on which the Common Stock is then listed or quoted for trading as reported by Bloomberg L.P., (B) if the Common Stock is then listed or quoted for trading on








 
the OTC Bulletin Board, the volume-weighted average closing prices of the Common Stock on the OTC Bulletin Board, or (C) if the Common Stock is not then listed or quoted for trading on the
OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the closing bid prices
per share of the Common Stock so reported. 







 ANNEX B 

Accredited Investor 
 An “accredited investor” is: 
 1. Any bank as defined in section 3(a)(2)
of the Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities
Exchange Act of 1934; any insurance company as defined in section 2(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in section 2(a)(48) of that Act; any Small
Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency
or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974
if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total
assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors; 
 2. Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940; 
 3. Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring
the securities offered, with total assets in excess of $5,000,000; 
 4. Any director, executive officer, or general partner of
the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer; 
 5. Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000; 

6. Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that
person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; 
 7. Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in
§ 230.506(b)(2)(ii); and 
 8. Any entity in which all of the equity owners are accredited investors. 

The term “net worth” means the excess of total assets over total liabilities. In computing net worth for the purpose of
(5) above, (i) persons must exclude the value of their primary residence, and (ii) persons may exclude any mortgage or any other debt secured by their primary residence that does not exceed the fair market value of the
residence. If, however, the amount of such debt exceeds the fair market value of the residence, persons are required to deduct the excess liability from the net worth calculation. 







 ANNEX C 

Authorized and Outstanding Capital Stock 
 As of the date of the Agreement, authorized capital of the Company includes 205,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock, of which 1,250,000 shares have been designated as 9%
Cumulative Convertible Preferred Stock; 205,000 shares have been designated as Series A Junior Participating Preferred Stock; 37,500 shares have been designated as Series B Convertible Preferred Stock; and 3,507,500 shares remain undesignated.

 As of the date of the Agreement, the Company has 78,858,197 shares of Common Stock and 37,500 shares of Series B Convertible
Preferred Stock outstanding. 
 As of the date of the Agreement, the Company’s issued and outstanding options and other
securities convertible into, or exercisable for, shares of the Company’s Common Stock consist of the following: 
 1.
9,813,766 shares of Common Stock authorized for issuance under the Company’s 2006 Stock Incentive Plan; and 
 2. 5,203,426
shares of Common Stock subject to issued and outstanding options under the Company’s 1996 Stock Incentive Plan; and 
 3.
350,000 shares of Common Stock subject to issued and outstanding options outside of the Company’s 2006 Stock Incentive Plan and 1996 Stock Incentive Plan; and 
 4. 24,126,952 shares of Common Stock reserved for issuance upon the exercise of outstanding warrants; and 
 5. 37,500 shares of Series B Convertible Preferred Stock, each share of which is convertible into approximately 0.09812 shares of Common Stock; and 

6. 71,728 shares of Common Stock potentially issuable upon repayment of an advance to fund the Company’s expenses for its clinical
study in patients with Mild Cognitive Impairment, such number of shares based upon the balance of the advance and accrued interest as of September 30, 2011. 
 Each of the foregoing securities includes anti-dilution provisions in the event of stock dividends, stock splits or reclassifications of the Company’s Common Stock. 







 EXHIBIT A 

Form of Warrant 
 NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. ADDITIONALLY, THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AS SET FORTH IN THAT CERTAIN SECURITIES PURCHASE AGREEMENT DATED OCTOBER 20, 2011.

 COMMON STOCK PURCHASE WARRANT 
 CORTEX PHARMACEUTICALS, INC. 
  

			
	Warrant Shares: 1,691,367	 	Issue Date: October 20, 2011

 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Samyang Value Partners Co., Ltd. (the “Holder”) is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or prior to the close of business on the two year anniversary of the original Issue Date (the “Termination Date”) but not thereafter, to
subscribe for and purchase from Cortex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to One Million Six Hundred Ninety-One Thousand Three Hundred Sixty-Seven (1,691,367) shares (the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). 
 Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms shall have the meanings set forth in this Section 1: 

“Business Day” shall mean any day except any Saturday, any Sunday, any day which is a federal legal
holiday in the United States or any day on which banking institutions in the State of California are authorized or required by law or other governmental action to close. 

“Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed. 







 “Trading Day” means a day on which the principal Trading
Market is open for trading. 
 “Trading Market” means a market or exchange on which the Common
Stock is then listed or quoted for trading, including, without limitation, the NYSE Amex Equities Market, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange, the OTC Bulletin Board or
a Pink OTC Market (or any successors to any of the foregoing). 
 “Transaction Documents” means
the Securities Purchase Agreement dated October 20, 2011 between the Company and the purchaser signatory thereto (the “Purchase Agreement”), as well as the other agreements and documents contemplated thereby. 

“Weighted Average Closing Price” means the price determined by the first of the following clauses that
applies: (A) if the Common Stock is then listed or quoted for trading on a Trading Market other than the OTC Bulletin Board or the Pink OTC Market, the volume-weighted average closing prices of the Common Stock on the Trading Market on which
the Common Stock is then listed or quoted for trading as reported by Bloomberg L.P., (B) if the Common Stock is then listed or quoted for trading on the OTC Bulletin Board, the volume-weighted average closing prices of the Common Stock on the
OTC Bulletin Board, or (C) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or
a similar organization or agency succeeding to its functions of reporting prices), the closing bid prices per share of the Common Stock so reported. 
 Section 2. Exercise. 
 a) Exercise of
Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise Form annexed hereto, the original Warrant certificate and payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. 
 b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $0.1035, subject to adjustment hereunder (the “Exercise Price”). 

c) Mechanics of Exercise. 
 i. Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company or the Company’s transfer agent to the Holder promptly after the date
of exercise. This Warrant shall be deemed to have been exercised on the first date on which all of the items in Section 2(a) above have been delivered to 

  
 2 








 
the Company. The Warrant Shares shall be deemed to have been issued, and Holder shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has
been properly exercised, with payment to the Company of the Exercise Price prior to the issuance of such shares, having been paid. 
 ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the
time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant. 
 iii. No Fractional Shares or Scrip. No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either
pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. 

iv. Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the
Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder.

 v. Closing of Books. The Company will not close its stockholder books or records in any manner which
prevents the timely exercise of this Warrant, pursuant to the terms hereof. 
 d) Representation by the
Holder; Restrictions. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant,
if not registered, will have restrictions upon resale imposed by state and federal securities laws and will contain one or more legends relating thereto. The Holder further acknowledges that the Warrant Shares may not be offered or sold except in
compliance with the Company’s right of first refusal contained in the Purchase Agreement and pursuant to an effective registration statement under the Securities Act or pursuant to an available exemption from, or in a transaction not subject
to, the registration requirements of the Securities Act and in accordance with applicable state securities laws as evidenced 

  
 3 








 
by a legal opinion of counsel to the transferor to such effect, the substance of which shall be reasonably acceptable to the Company. 

e) Call Provision. Subject to the provisions of this Section 2(e), if (i) the Weighted Average Closing
Price for each of 10 consecutive Trading Days (the “Measurement Period”) exceeds one and one-half (1.5) times the Exercise Price (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends
and the like after the original Issue Date) and (ii) the Holder is not in possession of any information that constitutes, or might constitute, material non-public information which was provided by the Company, then the Company may, within 3
Trading Days of the end of such Measurement Period, call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet been delivered (such right, a “Call”) for consideration equal to $0.001 per
Share. To exercise this right, the Company must deliver to the Holder an irrevocable written notice (a “Call Notice”); indicating therein the portion of unexercised portion of this Warrant to which such notice applies. If the
conditions set forth below for such Call are satisfied from the period from the date of the Call Notice through and including the Call Date (as defined below), then any portion of this Warrant subject to such Call Notice for which a Notice of
Exercise shall not have been received by the Call Date will be cancelled at 6:30 p.m. (Los Angeles time) on the tenth Trading Day after the date the Call Notice is received by the Holder (such date and time, the “Call Date”). Any
unexercised portion of this Warrant to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company covenants and agrees that it will honor all Notices of Exercise with respect to Warrant Shares
subject to a Call Notice that are tendered through 6:30 p.m. (Los Angeles time) on the Call Date. The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than all the Warrants shall first reduce to zero the
number of Warrant Shares subject to such Call Notice prior to reducing the remaining Warrant Shares available for purchase under this Warrant. For example, if (A) this Warrant then permits the Holder to acquire 100 Warrant Shares, (B) a
Call Notice pertains to 75 Warrant Shares, and (C) prior to 6:30 p.m. (Los Angeles time) on the Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x) on the Call Date the right under this Warrant to
acquire 25 Warrant Shares will be automatically cancelled, (y) the Company, in the time and manner required under this Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the exercises following receipt of the
Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to adjustment as herein provided and subject to subsequent Call Notices). Subject again to the provisions of this
Section 2(e), the Company may deliver subsequent Call Notices for any portion of this Warrant for which the Holder shall not have delivered a Notice of Exercise. Notwithstanding anything to the contrary set forth in this Warrant, the Company
may not deliver a Call Notice or require the cancellation of this Warrant (and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the Company shall have honored in accordance
with the terms of this Warrant all Notices of Exercise delivered by 6:30 p.m. (Los Angeles time) on the Call Date, and (2) the Common Stock shall be listed or quoted for trading on the Trading Market, and (3) there is a sufficient number
of authorized shares of Common Stock for issuance of all securities under the Transaction Documents. 

  
 4 








 Section 3. Certain Adjustments. 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into
a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 

b) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest
1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding. 
 c) Notice to Holder. Whenever the Exercise Price is adjusted
pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 

Section 4. Transfer of Warrant. 

a) Transferability. This Warrant evidenced hereby may not be pledged, sold, assigned or transferred. 

b) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual written notice to the contrary. 

  
 5 








 Section 5. Miscellaneous. 

a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i). 
 b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation
of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if
mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. 

d) Authorized Shares. 
 The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the
Warrant Shares upon the exercise of any purchase rights under this Warrant. 
 Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. 
 Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such
authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 
 e) Effect of Consolidation, Merger or Sale. Notwithstanding anything in this Warrant to the contrary, this Warrant shall expire upon any (i) consolidation or merger of the Company with another
entity, or any statutory exchange of securities with another entity, whereby the holders of voting capital stock of the Company immediately prior to such transaction hold less than 50% of the voting capital stock following such


  
 6 








 
transaction, (ii) sale or all or substantially all of the Company’s assets to another entity or (iii) liquidation of the Company. The Company shall give the Holder at least fifteen
(15) days advance notice of the closing of such transaction at its last address as it shall appear upon the Warrant Register of the Company; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not
affect the validity of the corporate action required to be specified in such notice. 
 f) Governing Law.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement. 

g) Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder or
the Company shall operate as a waiver of such right or otherwise prejudice Holder’s or the Company’s respective rights, powers or remedies. 
 h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the
Purchase Agreement. 
 i) Successors and Assigns. Subject to applicable securities laws, this Warrant and
the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. 

j) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of
the Company and the Holder. 
 k) Severability. Wherever possible, each provision of this Warrant shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or
invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 

l) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Warrant. 
 ******************** 

(Signature Page Follows) 

  
 7 








 IN WITNESS WHEREOF, the Company and the Holder have caused this Warrant to be executed by
their respective officers thereunto duly authorized. 
  

					
		 	CORTEX PHARMACEUTICALS, INC. 
	Dated: October 20, 2011	 		 	
			
		 	By:	 	  

		 		 	Name: Mark A. Varney, Ph.D.
		 		 	Title: Chief Executive Officer

 Accepted and agreed to this     day of
            , 2011 
  

			
	SAMYANG VALUE PARTNERS CO., LTD. 
		
	By:	 	  

		 	Name: Soung Jin Kim
		 	Title: President and Chief Executive Officer


  
 8 








 NOTICE OF EXERCISE 

 

	TO:	CORTEX PHARMACEUTICALS, INC. 


(1) The undersigned hereby elects to purchase             Warrant Shares of
the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 
 (2) Payment shall take the form of lawful money of the United States. 
 (3) Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned. 
 The Warrant Shares shall be delivered by
physical delivery of a certificate to: 
  

			
	  
	 	
		
	  
	 	
		
	  
	 	

 (4) The undersigned is an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7) or (a)(8) under the Securities Act of 1933, as amended. 
 [SIGNATURE OF HOLDER] 

 

			
	Name of Investing Entity:	 	  



			
	Signature of Authorized Signatory of Investing Entity:	 	  



			
	Name of Authorized Signatory:	 	  



			
	Title of Authorized Signatory:	 	  



			
	Date:	 	  









 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 
 this form and supply required information. 
 Do not use this form to exercise the
warrant.) 
 FOR VALUE RECEIVED, [            ] all of or
[            ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 

 

							
	  
	 	whose address is	 		 	
			
	  
	 	.	 	
			
	  
	 		 	

 Dated:             ,
         
  

							
				
		 	Holder’s Signature:	 	  
	 	
				
		 	Holder’s Address:	 	  
	 	
				
		 		 	  
	 	

  
 Signature Guaranteed:
                                         
                                        
                
 NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign the foregoing Warrant.